Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

VCYT

Veracyte Inc

May 17 • 04:00PM ET

22.88

Dollar change -0.52
Percentage change -2.22	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: ARKK VTI ARKG IWM VB VXF VBK IWN ARKW IBB

Index	RUT	P/E	-	EPS (ttm)	-0.93	Insider Own	0.89%	Shs Outstand	76.45M	Perf Week	7.07%
Market Cap	1.75B	Forward P/E	239.06	EPS next Y	0.10	Insider Trans	-2.86%	Shs Float	75.77M	Perf Month	19.17%
Income	-68.18M	PEG	-	EPS next Q	-0.04	Inst Own	108.45%	Short Float	5.80%	Perf Quarter	-7.52%
Sales	375.47M	P/S	4.66	EPS this Y	89.22%	Inst Trans	0.35%	Short Ratio	6.01	Perf Half Y	-8.55%
Book/sh	14.64	P/B	1.56	EPS next Y	187.01%	ROA	-5.78%	Short Interest	4.39M	Perf Year	-8.70%
Cash/sh	2.74	P/C	8.36	EPS next 5Y	-	ROE	-6.20%	52W Range	18.61 - 30.52	Perf YTD	-16.83%
Dividend Est.	-	P/FCF	66.43	EPS past 5Y	-10.52%	ROI	-6.05%	52W High	-25.03%	Beta	1.73
Dividend TTM	-	Quick Ratio	4.69	Sales past 5Y	34.42%	Gross Margin	62.24%	52W Low	22.94%	ATR (14)	0.94
Dividend Ex-Date	-	Current Ratio	5.00	EPS Y/Y TTM	-122.18%	Oper. Margin	-1.42%	RSI (14)	62.66	Volatility	3.98% 4.31%
Employees	815	Debt/Eq	0.01	Sales Y/Y TTM	20.66%	Profit Margin	-18.16%	Recom	1.89	Target Price	29.83
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	77.79%	Payout	-	Rel Volume	0.86	Prev Close	23.40
Sales Surprise	3.74%	EPS Surprise	87.42%	Sales Q/Q	17.50%	Earnings	May 07 AMC	Avg Volume	730.26K	Price	22.88
SMA20	10.28%	SMA50	9.31%	SMA200	-3.73%	Trades		Volume	628,696	Change	-2.22%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Reiterated	Needham	Buy	$30 → $33
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$33
Jan-07-22	Initiated	Stephens	Overweight	$52
Nov-18-21	Resumed	Goldman	Buy	$60
Jun-15-21	Initiated	Raymond James	Outperform	$45
Feb-18-21	Resumed	Needham	Buy	$88
Jan-28-21	Initiated	Truist	Buy	$61
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight	$48
Sep-09-20	Initiated	Morgan Stanley	Underweight	$35
Jul-31-19	Initiated	Lake Street	Buy	$35
Jul-02-19	Initiated	Needham	Buy	$33
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Nov-07-17	Downgrade	Janney	Buy → Neutral
Aug-31-17	Resumed	BTIG Research	Buy	$13
Nov-14-16	Resumed	Leerink Partners	Outperform	$12
Dec-18-15	Initiated	Cantor Fitzgerald	Buy	$13
Jun-11-15	Reiterated	Leerink Partners	Outperform	$11 → $13

Show Previous Ratings

May-15-24 05:04PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
May-13-24 09:55AM	Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to Trade (Zacks) +5.29%
May-08-24 03:13PM	Veracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:55AM	Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View (Zacks)
07:12AM	Q1 2024 Veracyte Inc Earnings Call (Thomson Reuters StreetEvents)
03:48AM	Loading…
03:48AM	Veracyte Inc (VCYT) (Q1 2024) Earnings Call Transcript Highlights: Strong Start with Revenue ... (GuruFocus.com)
May-07-24 10:55PM	VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:13PM	Veracyte: Q1 Earnings Snapshot (Associated Press Finance)
06:00PM	Veracyte Inc (VCYT) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strong Test Performance (GuruFocus.com)
04:05PM	Veracyte Announces First Quarter 2024 Financial Results (Business Wire)
May-06-24 04:05PM	14 Studies Presented at AUA 2024 Show Decipher Tests Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding (Business Wire)
Apr-22-24 05:00PM	Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
08:30AM	New Study Shows Veracytes Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance (Business Wire)
Apr-16-24 08:30AM	Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 (Business Wire)
Apr-02-24 10:33AM	What Makes Veracyte (VCYT) a Lucrative Investment? (Insider Monkey) -5.22%
05:55PM	Loading…
Feb-27-24 05:55PM	Veracytes Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines (Business Wire)
Feb-26-24 03:20PM	7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff (InvestorPlace) +6.22%
Feb-23-24 11:10AM	Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.87%
07:43AM	Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands (Zacks)
07:37AM	Q4 2023 Veracyte Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-22-24 06:05PM	Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:03PM	Veracyte: Q4 Earnings Snapshot (Associated Press Finance)
04:40PM	Veracyte Inc (VCYT) Reports 22% Revenue Growth in 2023, Maintains Positive Cash Flow Outlook (GuruFocus.com)
04:05PM	Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-21-24 05:00PM	Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference (Business Wire)
Feb-08-24 08:00AM	Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 (Business Wire)
Feb-06-24 08:15AM	Veracyte Completes Acquisition of C2i Genomics (Business Wire)
Jan-08-24 08:00AM	Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform (Business Wire) +13.10%
Dec-12-23 04:30PM	Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-01-23 04:05PM	Real-World Data Presented at SUO 2023 Show that Veracytes Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress (Business Wire)
08:30AM	Loading…
Nov-29-23 08:30AM	Clinical Validation Data Published in CHEST Demonstrate that Veracytes Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules (Business Wire)
Nov-22-23 08:30AM	Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023 (Business Wire)
Nov-08-23 04:39PM	Veracyte, Inc. (NASDAQ:VCYT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:57PM	Veracyte: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Third Quarter 2023 Financial Results (Business Wire)
04:00PM	Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally (Business Wire)
Nov-02-23 08:15AM	Veracyte to Participate in the Stephens Annual Investment Conference (Business Wire) +6.13%
Oct-27-23 08:30AM	Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development (Business Wire)
Oct-26-23 02:50PM	7 Undervalued Stocks That Analysts Love Right Now (InvestorPlace)
Oct-17-23 08:15AM	Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023 (Business Wire)
Oct-16-23 10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)
Oct-12-23 09:00AM	New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracytes Envisia Genomic Classifier for Patients with Interstitial Lung Disease (Business Wire) -5.82%
Oct-04-23 04:05PM	New Data from Phase 3 Trial Further Validate Prognostic Value of Veracytes Decipher Prostate Genomic Classifier (Business Wire)
Sep-28-23 04:05PM	New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracytes Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer (Business Wire)
08:15AM	Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 (Business Wire)
Sep-27-23 09:00AM	Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer (Business Wire)
Sep-21-23 04:05PM	Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting (Business Wire)
Sep-07-23 04:05PM	Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Companys Tests (Business Wire)
Sep-06-23 08:15AM	Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies (Business Wire)
Sep-02-23 06:15AM	Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors? (Motley Fool)
Aug-29-23 08:15AM	Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-22-23 08:15AM	Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer (Business Wire)
Aug-15-23 04:15PM	Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego (Business Wire)
Aug-08-23 06:05PM	Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:55PM	Veracyte: Q2 Earnings Snapshot (AP Finance)
04:05PM	Veracyte Announces Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 08:15AM	Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracytes Decipher Prostate Genomic Classifier in Prostate Cancer Treatment (Business Wire)
Jul-19-23 05:00PM	Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023 (Business Wire)
Jul-08-23 08:43PM	Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom (InvestorPlace)
Jun-20-23 08:31AM	New Data Suggest Veracytes Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer (Business Wire)
Jun-12-23 08:31AM	Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023 (Business Wire)
May-30-23 06:56AM	Veracyte, Inc.'s (NASDAQ:VCYT) Revenues Are Not Doing Enough For Some Investors (Simply Wall St.)
May-25-23 05:13PM	New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracytes Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer (Business Wire)
May-24-23 09:00AM	New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracytes Genomic Tests in Interstitial Lung Disease and Lung Cancer (Business Wire)
May-23-23 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
May-22-23 07:30AM	Here's Why This Little-Known Growth Stock Is a Buy (Motley Fool) +7.79%
May-12-23 06:15AM	Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer (Business Wire)
May-05-23 01:59PM	Veracyte, Inc. (NASDAQ:VCYT) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-04-23 06:25PM	Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Veracyte Announces First Quarter 2023 Financial Results (Business Wire)
09:45AM	New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules (Business Wire)
May-03-23 05:44PM	New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients (Business Wire)
08:30AM	Veracyte Announces Release of Inaugural ESG Report (Business Wire)
May-02-23 04:05PM	Data Published in "The Red Journal" Validate Clinical Utility of Veracytes Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer (Business Wire) -8.23%
May-01-23 05:35PM	Three Abstracts Focusing on the Clinical Utility of Veracytes Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference (Business Wire)
Apr-29-23 04:31PM	Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracytes Decipher Prostate Genomic Classifier (Business Wire)
Apr-27-23 04:05PM	Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting (Business Wire)
10:02AM	Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know (Zacks)
09:55AM	Wall Street Analysts See a 40.19% Upside in Veracyte (VCYT): Can the Stock Really Move This High? (Zacks)
Apr-18-23 09:48AM	The five-year returns have been strong for Veracyte (NASDAQ:VCYT) shareholders despite underlying losses increasing (Simply Wall St.)
Apr-17-23 08:30AM	New Data Reinforce Ability of Veracytes Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification (Business Wire)
Apr-13-23 05:00PM	Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023 (Business Wire) +7.24%
Apr-12-23 08:30AM	Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting (Business Wire)
Mar-23-23 06:54AM	Estimating The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT) (Simply Wall St.)
Mar-15-23 04:15PM	Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Companys Multi-Omics Capabilities and Tools for Biopharma Partners (Business Wire)
11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-11-23 12:11PM	Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank (Business Wire)
Mar-10-23 09:30AM	Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors? (Motley Fool) -8.78%
Feb-27-23 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
Feb-24-23 05:42AM	We're Interested To See How Veracyte (NASDAQ:VCYT) Uses Its Cash Hoard To Grow (Simply Wall St.)
Feb-22-23 06:15PM	Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.19%
04:05PM	Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results (Business Wire)
Feb-15-23 08:36AM	Data Published in "The Red Journal" Validate Prognostic Value of Veracytes Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer (Business Wire)
Feb-13-23 05:23PM	New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment (Business Wire)
10:14AM	Stay Long and Strong: Billionaire Ken Fisher Snaps Up These 2 Strong Buy Stocks (TipRanks)
Feb-06-23 05:00PM	Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023 (Business Wire)
Feb-01-23 04:05PM	Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium (Business Wire)
08:32AM	Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules (Business Wire)
Jan-24-23 10:23AM	Better Long-Term Buy in 2023: Exact Sciences or Veracyte? (Motley Fool)
Jan-23-23 09:00AM	Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors (GlobeNewswire) +5.75%

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EASTHAM KARIN	Director	Apr 01 '24	Option Exercise	13.19	10,000	131,900	43,125	Apr 02 04:17 PM
EASTHAM KARIN	Director	Apr 01 '24	Sale	21.65	10,000	216,528	33,125	Apr 02 04:17 PM
JONES EVAN/ FA	Director	Mar 01 '24	Option Exercise	13.19	10,000	131,900	47,601	Mar 05 05:28 PM
JONES EVAN/ FA	Director	Mar 01 '24	Sale	24.36	10,000	243,599	37,601	Mar 05 05:28 PM
JONES EVAN/ FA	Director	Jul 19 '23	Sale	30.17	3,090	93,232	35,173	Jul 24 05:06 PM
JONES EVAN/ FA	Director	Jul 19 '23	Sale	30.14	838	25,257	37,601	Jul 24 05:06 PM
BISHOP JOHN L	Director	Jul 18 '23	Option Exercise	6.37	10,000	63,700	43,125	Jul 19 08:35 PM
BISHOP JOHN L	Director	Jul 18 '23	Sale	30.50	10,000	305,000	33,125	Jul 19 08:35 PM
JONES EVAN/ FA	Director	Jul 18 '23	Sale	30.19	7,441	224,616	38,263	Jul 19 08:33 PM
JONES EVAN/ FA	Director	Jul 18 '23	Sale	30.16	2,324	70,090	38,439	Jul 19 08:33 PM
BISHOP JOHN L	Director	Jul 17 '23	Option Exercise	6.37	10,000	63,700	43,125	Jul 19 08:35 PM
JONES EVAN/ FA	Director	Jul 17 '23	Sale	30.07	23,949	720,106	45,704	Jul 19 08:33 PM
JONES EVAN/ FA	Director	Jul 17 '23	Sale	30.07	19,095	574,106	40,763	Jul 19 08:33 PM
BISHOP JOHN L	Director	Jul 17 '23	Sale	30.00	10,000	300,002	33,125	Jul 19 08:35 PM
Bhanji Muna	Director	Jun 16 '23	Sale	26.44	5,893	155,786	28,514	Jun 21 04:55 PM
Bhanji Muna	Director	May 30 '23	Sale	25.91	1,539	39,875	24,733	Jun 01 05:06 PM

Open in Screener

NKTR

Nektar Therapeutics

May 17 • 04:00PM ET

1.75

Dollar change -0.04
Percentage change -2.50	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

NKTR Nektar Therapeutics daily Stock Chart

Held by: VTI VXF SCHA PRFZ VHT SCHB NANC

Index	-	P/E	-	EPS (ttm)	-0.92	Insider Own	2.91%	Shs Outstand	191.38M	Perf Week	-0.28%
Market Cap	322.25M	Forward P/E	-	EPS next Y	-0.76	Insider Trans	-2.36%	Shs Float	178.28M	Perf Month	32.95%
Income	-175.84M	PEG	-	EPS next Q	-0.20	Inst Own	59.65%	Short Float	1.99%	Perf Quarter	146.52%
Sales	90.17M	P/S	3.57	EPS this Y	44.31%	Inst Trans	-4.28%	Short Ratio	1.37	Perf Half Y	234.29%
Book/sh	0.69	P/B	2.54	EPS next Y	5.57%	ROA	-36.72%	Short Interest	3.54M	Perf Year	150.71%
Cash/sh	1.58	P/C	1.11	EPS next 5Y	-7.30%	ROE	-95.68%	52W Range	0.41 - 1.93	Perf YTD	210.62%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-51.83%	52W High	-8.97%	Beta	0.80
Dividend TTM	-	Quick Ratio	5.79	Sales past 5Y	-20.42%	Gross Margin	60.91%	52W Low	325.35%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	6.10	EPS Y/Y TTM	58.37%	Oper. Margin	-147.13%	RSI (14)	61.96	Volatility	7.08% 9.30%
Employees	137	Debt/Eq	1.83	Sales Y/Y TTM	1.51%	Profit Margin	-195.02%	Recom	3.00	Target Price	1.60
Option/Short	Yes / Yes	LT Debt/Eq	1.68	EPS Q/Q	73.95%	Payout	-	Rel Volume	0.44	Prev Close	1.80
Sales Surprise	41.05%	EPS Surprise	0.00%	Sales Q/Q	0.21%	Earnings	May 09 AMC	Avg Volume	2.59M	Price	1.75
SMA20	12.68%	SMA50	37.74%	SMA200	129.79%	Trades		Volume	1,142,517	Change	-2.50%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3
Mar-15-22	Downgrade	Mizuho	Buy → Neutral	$35 → $8
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform
Mar-14-22	Downgrade	Stifel	Buy → Hold	$24 → $5
Mar-14-22	Downgrade	BTIG Research	Buy → Neutral
Mar-14-22	Downgrade	BofA Securities	Neutral → Underperform	$18 → $6
Mar-09-22	Upgrade	Oppenheimer	Perform → Outperform	$21
Nov-08-21	Upgrade	The Benchmark Company	Hold → Buy	$20
Sep-10-21	Initiated	BofA Securities	Neutral	$18
Jun-28-21	Upgrade	Stifel	Hold → Buy	$22 → $24
May-18-21	Resumed	Goldman	Neutral	$24
Feb-22-21	Downgrade	The Benchmark Company	Buy → Hold
Jan-06-21	Initiated	Stifel	Hold	$18

Show Previous Ratings

May-10-24 04:41PM	Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript (Insider Monkey) +10.00%
03:14PM	Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview (GuruFocus.com)
11:33AM	Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates (Zacks)
10:35AM	Q1 2024 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
May-09-24 05:39PM	Nektar: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Loading…
04:15PM	Nektar Therapeutics Reports First Quarter 2024 Financial Results (PR Newswire)
May-02-24 06:00PM	Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets (PR Newswire)
Apr-03-24 11:30AM	Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue? (Zacks) +9.47%
Mar-25-24 10:00AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-22-24 02:00PM	Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (PR Newswire)
Mar-06-24 12:33PM	Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata (Zacks)
Mar-05-24 10:07AM	Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat (Zacks)
09:13AM	Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata (PR Newswire)
07:19AM	Q4 2023 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
05:30PM	Loading…
Mar-04-24 05:30PM	Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +15.38%
04:51PM	Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results (GuruFocus.com)
04:42PM	Nektar: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results (PR Newswire)
08:30AM	Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX (PR Newswire)
Feb-27-24 06:00PM	Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference (PR Newswire) +11.94%
Feb-26-24 06:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets (PR Newswire)
Feb-20-24 10:00AM	Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know (Zacks) -6.78%
Jan-03-24 06:00PM	Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA (PR Newswire) -6.36%
Dec-11-23 06:00PM	Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Dec-07-23 11:31AM	Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-09-23 08:39AM	Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.00%
Nov-08-23 11:47AM	Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss (Zacks) -8.76%
Nov-07-23 05:28PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2023 Financial Results (PR Newswire)
06:00PM	Loading…
Oct-31-23 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets (PR Newswire)
Oct-26-23 10:02AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey) -7.11%
Oct-13-23 08:30AM	Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress (PR Newswire)
Oct-02-23 09:00AM	Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy (PR Newswire)
Sep-27-23 09:00AM	Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer (PR Newswire)
Sep-14-23 07:54AM	Nektar (NKTR) Up on Positive New Data From Eczema Study (Zacks)
Sep-13-23 09:00AM	Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Sep-07-23 11:31AM	Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report? (Zacks)
Sep-06-23 06:00PM	Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th (PR Newswire)
Aug-17-23 07:02PM	RA Capital Management, L.P. Acquires Significant Stake in Nektar Therapeutics (GuruFocus.com) -6.26%
Aug-09-23 09:25AM	Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss (Zacks) -8.94%
Aug-08-23 05:30PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:23PM	Nektar: Q2 Earnings Snapshot (AP Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
11:08AM	Nektar Therapeutics sues Lilly for breach of contract around skin drug (American City Business Journals)
Aug-07-23 10:23AM	Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment (Reuters) +91.51%
06:30AM	Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company (PR Newswire)
Aug-01-23 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets (PR Newswire)
Jul-24-23 03:48AM	Zoetis (ZTS) Moves 6.9% Higher: Will This Strength Last? (Zacks) -5.69%
Jul-16-23 08:49AM	Nektar Therapeutics (NASDAQ:NKTR) is largely controlled by institutional shareholders who own 70% of the company (Simply Wall St.)
Jun-12-23 06:00PM	Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference (PR Newswire)
Jun-08-23 12:55PM	Investors Don't See Light At End Of Nektar Therapeutics' (NASDAQ:NKTR) Tunnel (Simply Wall St.)
11:31AM	Why Is Nektar (NKTR) Down 19.7% Since Last Earnings Report? (Zacks)
May-10-23 11:28AM	Nektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call Transcript (Insider Monkey)
09:16AM	Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat (Zacks)
May-09-23 06:45PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:41PM	Nektar: Q1 Earnings Snapshot (AP Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
May-08-23 09:29AM	Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More (Zacks) -5.94%
May-04-23 10:00AM	Earnings Preview: Marinus Pharmaceuticals (MRNS) Q1 Earnings Expected to Decline (Zacks)
May-02-23 10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-27-23 08:30AM	Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development (PR Newswire)
Apr-19-23 08:38AM	Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics (Zacks)
Apr-17-23 05:00PM	Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan (PR Newswire) +6.26%
Apr-16-23 06:30AM	7 Sorry Pharma Stocks to Sell in April Before Its Too Late (InvestorPlace)
Apr-13-23 10:59AM	Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio (Zacks) +10.16%
Apr-11-23 08:57AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics (Zacks) +10.53%
Apr-10-23 10:07AM	5 Stocks to Buy as the Drug Industry Rebounds in 2023 (Zacks) +6.57%
Apr-02-23 08:27AM	We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully (Simply Wall St.)
Mar-30-23 11:30AM	Why Is Nektar (NKTR) Down 51.9% Since Last Earnings Report? (Zacks) -12.42%
Mar-29-23 05:44PM	Crane Set to Join S&P MidCap 400; PacWest Bancorp to Join S&P SmallCap 600 (PR Newswire)
Mar-24-23 12:00PM	Nektar (NKTR) Upgraded to Buy: Here's Why (Zacks)
Mar-22-23 09:35AM	Down -69.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Nektar (NKTR) (Zacks) -9.73%
Mar-14-23 03:43AM	Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock? (Zacks)
Feb-28-23 05:15PM	Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results (PR Newswire)
Feb-24-23 10:23AM	Why Nektar Therapeutics Stock Is Plunging Today (Benzinga) -49.66%
07:29AM	Boeing stock slips after deliveries of 787s halted; Beyond Meat shares rally after plant-food makers results (MarketWatch)
Feb-23-23 06:20PM	UPDATE 1-Nektar Therapeutics' autoimmune disease drug fails mid-stage study (Reuters)
05:24PM	Nektar stock drops more than 30% after study involving lupus treatment will not go forward (MarketWatch)
04:30PM	Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus (PR Newswire)
Jan-09-23 09:04AM	Concert (CNCE) Moves 19.3% Higher: Will This Strength Last? (Zacks)
Jan-04-23 09:00AM	Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA (PR Newswire) +6.85%
Dec-12-22 10:05AM	Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Dec-05-22 08:00AM	Nektar Therapeutics to Host Investor & Analyst Event on December 12th (PR Newswire)
Nov-10-22 09:05AM	Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire) +8.66%
07:58AM	Nektar Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-09-22 09:00AM	Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy (PR Newswire) -5.54%
Nov-04-22 12:35PM	Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates (Zacks) +5.90%
Nov-03-22 06:35PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-28-22 10:00AM	ImmunoGen (IMGN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-22 10:02AM	Nektar Therapeutics (NKTR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-25-22 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets (PR Newswire)
Oct-24-22 07:55AM	Here's Why We're Watching Nektar Therapeutics' (NASDAQ:NKTR) Cash Burn Situation (Simply Wall St.)
Oct-11-22 05:13PM	Why a S.F. biotech and its potential merger partner pulled the plug on talks (American City Business Journals)
Oct-07-22 03:42PM	Longtime S.F. biotech in talks with London company on 'combination' (American City Business Journals)
11:21AM	PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics (Benzinga)
Sep-07-22 01:15AM	Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress (PR Newswire)
Aug-21-22 09:57AM	Nektar Therapeutics (NASDAQ:NKTR shareholders incur further losses as stock declines 11% this week, taking five-year losses to 75% (Simply Wall St.)
Aug-16-22 08:30AM	Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma (PR Newswire)

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Deep Track Capital, LP	10% Owner	May 10 '24	Sale	1.78	56,000	99,630	18,344,000	May 13 04:36 PM
ROBIN HOWARD W	President & CEO	Feb 20 '24	Sale	0.68	20,033	13,622	879,889	Feb 22 08:16 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 20 '24	Sale	0.68	9,014	6,130	265,025	Feb 22 08:19 PM
Wilson Mark Andrew	Chief Legal Officer	Feb 20 '24	Sale	0.68	7,606	5,172	236,674	Feb 22 08:17 PM
ROBIN HOWARD W	President & CEO	Nov 17 '23	Sale	0.49	19,877	9,740	899,922	Nov 20 08:58 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 17 '23	Sale	0.49	9,646	4,727	274,039	Nov 20 09:02 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 17 '23	Sale	0.49	7,179	3,518	243,780	Nov 20 09:00 PM
Curet Myriam	Director	Sep 18 '23	Sale	0.69	4,359	3,008	27,418	Sep 20 08:09 PM
Ajer Jeffrey Robert	Director	Sep 18 '23	Sale	0.69	4,359	3,008	34,153	Sep 20 08:06 PM
ROBIN HOWARD W	President & CEO	Aug 16 '23	Sale	0.78	19,998	15,598	919,799	Aug 17 08:06 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 16 '23	Sale	0.78	9,703	7,568	283,685	Aug 17 08:08 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 16 '23	Sale	0.78	7,221	5,632	250,959	Aug 17 08:07 PM
WHITFIELD ROY A	Director	Jun 14 '23	Sale	0.57	30,000	17,100	216,250	Jun 15 06:26 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

VCYT

Veracyte Inc

NKTR

Nektar Therapeutics

Upgrade your FINVIZ experience